List of Excipients in Branded Drug CAMCEVI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Accord BioPharma Inc	CAMCEVI	leuprolide	69448-014	METHYLPYRROLIDONE	2039-01-01
Accord BioPharma Inc	CAMCEVI	leuprolide	69448-014	POLYLACTIDE	2039-01-01
Accord BioPharma Inc	CAMCEVI	leuprolide	69448-023	METHYLPYRROLIDONE	2039-01-01
Accord BioPharma Inc	CAMCEVI	leuprolide	69448-023	POLYLACTIDE	2039-01-01
Foresee Pharmaceuticals Co Ltd	CAMCEVI	leuprolide	72851-042	METHYLPYRROLIDONE	2039-01-01

# CAMCEVI Excipient Strategy and Commercial Opportunities: PLGA Depot Formulation, Regulatory Position, and Generic Risk

Last updated: August 28, 2026

CAMCEVI is a six-month subcutaneous depot injection of leuprolide mesylate for advanced prostate cancer. Its commercial differentiation depends on a biodegradable poly(DL-lactide-co-glycolide), or PLGA, delivery system combined with N-methyl-2-pyrrolidone, or NMP. The formulation avoids repeated intramuscular administration and places excipient performance, syringe compatibility, depot formation, and injection handling at the center of the product’s value proposition.

The main commercial opportunities are specialized PLGA and NMP supply, excipient-grade equivalence, device and container-closure development, analytical testing, formulation licensing, and complex generic development. The principal barriers are depot reproducibility, peptide stability, burst-release control, injection force, manufacturing scale-up, and the need to demonstrate pharmaceutical equivalence for a complex long-acting injectable.

What is CAMCEVI and how does its excipient system work?

CAMCEVI contains leuprolide mesylate in a polymeric delivery system administered subcutaneously once every six months. The active drug is a gonadotropin-releasing hormone agonist that suppresses testosterone production after an initial hormone surge.

The formulation uses:

Component	Function	Commercial relevance
Leuprolide mesylate	Active pharmaceutical ingredient	Peptide API requiring stability control
Poly(DL-lactide-co-glycolide)	Biodegradable depot-forming polymer	Controls drug release over approximately six months
N-methyl-2-pyrrolidone	Solvent and polymer vehicle	Supports injectable processing and in situ depot formation
Prefilled syringe system	Delivery and dose presentation	Affects injection force, storage, usability, and product differentiation

After injection, the solvent diffuses into surrounding tissue and the PLGA polymer precipitates or solidifies into a depot. Leuprolide release then occurs through a combination of diffusion, water penetration, polymer erosion, and degradation.

The FDA label identifies NMP and PLGA as inactive ingredients in CAMCEVI. The label does not identify conventional surfactant- or preservative-driven delivery as the primary release mechanism. [1]

What excipients protect CAMCEVI’s six-month release profile?

PLGA is the critical functional excipient. Its molecular weight, lactide-to-glycolide ratio, end-group chemistry, residual monomer content, particle or polymer morphology, and water content can alter depot performance.

PLGA design variables

Variable	Effect on CAMCEVI-type depot
Lactide:glycolide ratio	Higher glycolide content generally increases water uptake and degradation rate
Polymer molecular weight	Higher molecular weight can slow degradation and prolong release
End-group chemistry	Acid- or ester-terminated PLGA changes polymer hydration and local acidity
Residual moisture	Can accelerate hydrolysis and shorten shelf life
Residual solvent	Can affect viscosity, precipitation, and injection performance
Polymer concentration	Influences drug loading, depot volume, and syringe force
Polymer batch consistency	Controls release reproducibility and manufacturing yield

NMP has a dual role. It dissolves or disperses the polymer system during manufacture, and it allows the formulation to be delivered as an injectable liquid before depot formation. NMP concentration affects viscosity, tissue tolerability, solvent exchange, depot geometry, and initial drug release.

For suppliers, the commercial value is not limited to selling generic PLGA. A suitable material must be qualified for a specific long-acting injectable process, with tight controls over molecular weight distribution, residual solvents, water content, bioburden, endotoxin, and degradation profile.

What commercial opportunities exist for CAMCEVI excipient suppliers?

The strongest opportunities are in qualified excipient systems rather than commodity raw materials.

Pharmaceutical-grade PLGA supply

CAMCEVI-type products require PLGA with consistent physicochemical attributes. Suppliers can create value through:

• Narrow molecular-weight specifications
• Controlled lactide:glycolide ratios
• Low residual solvent and moisture levels
• Defined acid or ester end groups
• Injectable-grade documentation
• Lot-to-lot release-profile correlation
• Regulatory support for DMF or equivalent quality packages

A supplier able to demonstrate equivalence across multiple manufacturing lots can reduce customer development time. The opportunity is particularly strong for second-source qualification because a single-source polymer can create supply and regulatory risk for a long-acting injectable.

NMP supply and solvent control

NMP is a well-established pharmaceutical solvent, but long-acting injectable manufacturers require tight control of:

• Assay and identity
• Water content
• Residual impurities
• Peroxide and degradation products
• Container compatibility
• Extractables and leachables
• Sterility and endotoxin controls where applicable

NMP suppliers can compete through validated pharmaceutical manufacturing, regional inventory, container-closure compatibility, and regulatory support rather than price alone.

Excipient premixes

A higher-value model is a ready-to-use PLGA/NMP premix with defined viscosity, polymer concentration, and release characteristics. Such a product could reduce formulation variability and simplify manufacturing transfer.

The supplier would need to establish:

1. Polymer and solvent homogeneity.
2. Stability during storage.
3. Compatibility with the final syringe.
4. Reproducible in situ depot formation.
5. A control strategy for viscosity and injection force.
6. A defensible regulatory change package.

Premixes may be commercially attractive for smaller drug developers that lack in-house polymer formulation capability.

What formulation patents protect CAMCEVI-type products?

Protection for CAMCEVI-type products can arise from several patent categories:

Patent category	Potential protected subject matter
Composition	Leuprolide concentration, PLGA identity, NMP ratio, and depot composition
Formulation	Specific polymer molecular weight, end group, solvent content, and drug loading
Method of treatment	Six-month administration of leuprolide mesylate for prostate cancer
Manufacturing	Mixing, sterilization, filling, polymer dissolution, and control of residual solvent
Device	Prefilled syringe, dual-chamber presentation, needle configuration, or administration system
Release profile	Defined initial burst, testosterone suppression, and six-month pharmacokinetic behavior
Stability	Storage conditions and protection against polymer or peptide degradation

A commercial competitor should distinguish between patents directed to the approved product and broader patents covering PLGA depots or leuprolide delivery generally. Broad platform patents may create freedom-to-operate issues even where a competitor uses different polymer ratios.

How strong is the patent estate for CAMCEVI?

The formulation is more difficult to design around than a conventional immediate-release injection because the product’s performance depends on multiple interacting variables. A competitor may avoid literal infringement by changing polymer composition or solvent ratio, but it must still reproduce a six-month release profile and acceptable injection characteristics.

The practical strength of the estate depends on:

• The scope of issued formulation claims
• Whether claims cover functional release parameters
• Patent term and patent-term adjustment
• Orange Book listing status
• Continuation applications
• Manufacturing and device claims
• Clinical method-of-use claims
• The ability to establish non-infringement through a Paragraph IV certification

The public FDA prescribing information confirms the formulation components but does not, by itself, establish the scope or enforceability of CAMCEVI’s patent rights. Patent claims should be assessed against the current FDA Orange Book, USPTO records, and any district court filings. [1-3]

What is the FDA regulatory status of CAMCEVI?

The FDA approved CAMCEVI in May 2023 for the treatment of advanced prostate cancer. It is marketed by Accord BioPharma, Inc., and is supplied as a six-month subcutaneous depot injection. [1,4]

Regulatory item	Status
Active ingredient	Leuprolide mesylate
Dosage form	Injectable polymeric depot
Route	Subcutaneous
Dosing interval	Every six months
Approved indication	Advanced prostate cancer
FDA pathway	New drug application approval
Approval year	2023
Biosimilar pathway	Not applicable

CAMCEVI is a peptide-based drug product, but it is not a biologic for purposes of the biosimilar pathway. A competing product would generally pursue an abbreviated or hybrid regulatory strategy based on the applicable FDA pathway, rather than a biosimilar application under the Public Health Service Act.

When does CAMCEVI lose exclusivity?

CAMCEVI’s exclusivity timeline has two separate components: regulatory exclusivity and patent exclusivity.

FDA approval creates the applicable period of regulatory protection under the approved application. Patent protection may extend beyond, or expire before, regulatory exclusivity depending on filing dates, patent-term adjustment, patent-term extension, and the scope of listed patents.

Exclusivity issue	Business impact
New drug exclusivity	Limits certain competing applications for the statutory period
Formulation patents	Can delay competing long-acting injectable products
Method-of-use patents	May require labeling or indication carve-outs
Manufacturing patents	Can complicate non-infringing commercial scale-up
Device patents	Can affect prefilled syringe and administration design
Pediatric extension	Could add six months if applicable
Patent-term extension	May extend one qualifying patent after regulatory approval

An exact generic-entry date should not be inferred solely from the 2023 approval date. The relevant date depends on the complete Orange Book patent listing, any six-month pediatric extension, court outcomes, and settlement terms.

Are Paragraph IV challenges likely for CAMCEVI?

Paragraph IV risk is meaningful but technically demanding. A challenger would need to address more than the identity of leuprolide.

Key generic development barriers

• Demonstrating pharmaceutical equivalence for a complex depot.
• Matching the six-month release profile.
• Controlling the initial leuprolide burst.
• Establishing comparable testosterone suppression.
• Demonstrating acceptable injection force and depot tolerability.
• Managing peptide degradation products.
• Proving stability in the final syringe.
• Designing around listed formulation claims.
• Producing a commercially scalable sterile process.

A Paragraph IV challenger could attack patent validity, argue non-infringement, or claim that a listed patent is not relevant to the proposed product. The commercial risk is substantial because a technically different formulation may require extensive clinical or pharmacokinetic data even if it avoids literal patent infringement.

What generic launch scenarios exist for CAMCEVI?

Scenario 1: Six-month PLGA/NMP depot

This is the closest competitive product. It may offer the strongest clinical and commercial substitution profile but faces the highest risk of patent overlap and formulation-development failure.

Scenario 2: Different biodegradable polymer system

A competitor could use another polymer or a different solvent system. This may reduce infringement exposure but creates new requirements for tissue tolerability, release control, sterility, and clinical comparability.

Scenario 3: Microsphere formulation

A conventional injectable microsphere could provide six-month release. The manufacturing process would differ materially from an in situ depot, but the product would still face complex particle-size, encapsulation-efficiency, burst-release, and syringeability requirements.

Scenario 4: Alternative leuprolide presentation

Monthly, three-month, or four-month leuprolide products could compete for the same patients without directly duplicating CAMCEVI’s six-month formulation. This is a lower-risk route from a patent perspective but offers less direct substitution.

How does CAMCEVI compare with other leuprolide products?

Product	Active ingredient	Approximate dosing interval	Delivery approach	Competitive implication
CAMCEVI	Leuprolide mesylate	Six months	Subcutaneous polymeric depot	Reduced administration frequency
ELIGARD	Leuprolide acetate	One, three, four, or six months depending on strength	In situ polymeric depot	Established depot platform and physician familiarity
LUPRON DEPOT	Leuprolide acetate	Monthly to six months depending on product	Intramuscular microsphere depot	Broad historical use and established supply chain
FENSOLVI	Leuprolide acetate	Six months	Subcutaneous polymeric depot	Pediatric prostate-cancer indication and different market segment

CAMCEVI competes most directly with six-month leuprolide products. Its commercial advantage is the subcutaneous route and six-month dosing interval. Its commercial disadvantages include the need for confidence in a newer product, reimbursement access, administration training, and competition from established depot brands.

What manufacturing and IP barriers affect CAMCEVI competitors?

The most important manufacturing barrier is release-profile control. A small change in polymer molecular weight, solvent ratio, water content, mixing energy, or filling conditions can affect drug release and injection performance.

Critical process controls

• Polymer dissolution or dispersion
• Leuprolide uniformity
• Water and residual solvent content
• Mixing temperature and time
• Bulk viscosity
• Sterile filtration or aseptic processing
• Syringe filling accuracy
• Needle and syringe compatibility
• Container-closure integrity
• Particulate control
• In-use administration performance

Sterilization is a major design constraint. Terminal sterilization may damage the peptide or alter the polymer, while aseptic processing raises manufacturing cost and operational complexity.

A competitor also needs freedom to operate across the formulation, filling process, syringe system, and method of administration. Avoiding one composition claim does not eliminate risk from process or device patents.

What licensing deals could create value around CAMCEVI technology?

Potential licensing structures include:

Licensing target	Commercial use
PLGA platform license	Development of additional peptide or small-molecule depots
Excipient supply agreement	Preferred or exclusive supply of qualified PLGA
Regional commercialization license	Expansion outside the originator’s core markets
Device license	Prefilled syringe or administration technology
Formulation development agreement	Custom long-acting injectable programs
Manufacturing technology transfer	Contract development and manufacturing
Generic technology license	Authorized generic or settlement-linked supply

The most valuable asset is likely to be a validated formulation and manufacturing package, not NMP or PLGA considered separately. A license that includes process parameters, analytical methods, stability data, scale-up history, and regulatory support can materially reduce development time.

What revenue exposure does CAMCEVI create?

CAMCEVI participates in a large established market for androgen-deprivation therapy. Revenue exposure is linked to:

• Conversion from monthly or three-month injections.
• Payer coverage and reimbursement.
• Physician preference for subcutaneous administration.
• Six-month adherence and reduced office visits.
• Pricing relative to ELIGARD and LUPRON DEPOT.
• Availability of competing leuprolide and other GnRH therapies.
• Urology and oncology clinic purchasing behavior.

A six-month product can support higher per-injection pricing while reducing administration frequency. The commercial model depends on whether payers and providers recognize the value of fewer visits and whether reimbursement adequately covers the product and administration costs.

Key Takeaways

• CAMCEVI uses PLGA and NMP to create a six-month subcutaneous leuprolide depot.
• PLGA attributes, NMP quality, polymer-solvent ratio, and syringe compatibility are the central excipient strategy issues.
• The best excipient opportunity is a qualified PLGA/NMP system with reproducible release performance and regulatory documentation.
• Generic development is technically difficult because pharmaceutical equivalence requires matching depot behavior, not merely leuprolide strength.
• CAMCEVI is subject to patent, regulatory-exclusivity, formulation, manufacturing, and device risks.
• CAMCEVI competes most directly with six-month ELIGARD and LUPRON DEPOT products.
• Platform licensing, second-source excipient supply, device partnerships, and complex generic development are the main commercial opportunities.
• An exact loss-of-exclusivity date requires review of current Orange Book listings, USPTO records, and litigation or settlement developments.

FAQs About CAMCEVI Excipients and Commercial Strategy

Is NMP safe for use in CAMCEVI?

NMP is used as a pharmaceutical solvent and is identified in the FDA-approved CAMCEVI formulation. Its commercial risk is controlled through formulation-specific limits, impurity testing, container compatibility, and local tolerability assessment.

Can PLGA be replaced in a CAMCEVI generic?

Yes, a competitor could pursue a different polymer system, but the replacement would need to provide comparable release duration, peptide stability, tissue tolerability, injection performance, and regulatory support.

Is CAMCEVI a biosimilar?

No. CAMCEVI is a peptide-based drug product approved through an NDA pathway. A competing product would not automatically qualify as a biosimilar under the biologics statute.

Does CAMCEVI have a six-month patent term?

The six-month dosing interval does not determine patent duration. Patent expiration depends on the specific filing, issuance, patent-term adjustment, patent-term extension, and enforceability of each relevant patent.

Which excipient is most important for CAMCEVI performance?

PLGA is the primary release-controlling excipient. NMP is also critical because it governs injectability, depot formation, solvent exchange, and early release behavior.

References

1. U.S. Food and Drug Administration. (2023). CAMCEVI (leuprolide mesylate) injection prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. United States Patent and Trademark Office. (2024). Patent Center and patent term information databases.
4. Accord BioPharma, Inc. (2023). Accord BioPharma announces FDA approval of CAMCEVI for advanced prostate cancer.
5. U.S. Food and Drug Administration. (2023). Drugs@FDA: CAMCEVI application and regulatory records.